JP2022507485A5 - - Google Patents

Info

Publication number
JP2022507485A5
JP2022507485A5 JP2021526459A JP2021526459A JP2022507485A5 JP 2022507485 A5 JP2022507485 A5 JP 2022507485A5 JP 2021526459 A JP2021526459 A JP 2021526459A JP 2021526459 A JP2021526459 A JP 2021526459A JP 2022507485 A5 JP2022507485 A5 JP 2022507485A5
Authority
JP
Japan
Application number
JP2021526459A
Other languages
Japanese (ja)
Other versions
JP2022507485A (ja
JPWO2020102777A5 (https=
JP7785284B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061884 external-priority patent/WO2020102777A1/en
Publication of JP2022507485A publication Critical patent/JP2022507485A/ja
Publication of JP2022507485A5 publication Critical patent/JP2022507485A5/ja
Publication of JPWO2020102777A5 publication Critical patent/JPWO2020102777A5/ja
Priority to JP2025203085A priority Critical patent/JP2026053336A/ja
Application granted granted Critical
Publication of JP7785284B2 publication Critical patent/JP7785284B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526459A 2018-11-16 2019-11-15 Cd38抗体とicam1抗体およびそれらの使用 Active JP7785284B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203085A JP2026053336A (ja) 2018-11-16 2025-11-25 Cd38抗体とicam1抗体およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768566P 2018-11-16 2018-11-16
US62/768,566 2018-11-16
PCT/US2019/061884 WO2020102777A1 (en) 2018-11-16 2019-11-15 Cd38 and icam1 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203085A Division JP2026053336A (ja) 2018-11-16 2025-11-25 Cd38抗体とicam1抗体およびそれらの使用

Publications (4)

Publication Number Publication Date
JP2022507485A JP2022507485A (ja) 2022-01-18
JP2022507485A5 true JP2022507485A5 (https=) 2022-11-22
JPWO2020102777A5 JPWO2020102777A5 (https=) 2022-11-22
JP7785284B2 JP7785284B2 (ja) 2025-12-15

Family

ID=70731683

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526459A Active JP7785284B2 (ja) 2018-11-16 2019-11-15 Cd38抗体とicam1抗体およびそれらの使用
JP2025203085A Pending JP2026053336A (ja) 2018-11-16 2025-11-25 Cd38抗体とicam1抗体およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203085A Pending JP2026053336A (ja) 2018-11-16 2025-11-25 Cd38抗体とicam1抗体およびそれらの使用

Country Status (5)

Country Link
US (1) US12583932B2 (https=)
EP (1) EP3883967A4 (https=)
JP (2) JP7785284B2 (https=)
CN (2) CN120399084A (https=)
WO (1) WO2020102777A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12583932B2 (en) 2018-11-16 2026-03-24 Virtuoso Binco, Inc. CD38 and ICAM1 antibodies and uses thereof
US20220411508A1 (en) * 2019-09-09 2022-12-29 The Regents Of The University Of California Compositions and methods for making and using multispecific antibodies
JP2023526605A (ja) * 2020-05-14 2023-06-22 ヴィルトゥオーソ ビンコ,インク. ヒト化cd38およびicam1抗体、ならびにそれらの使用
WO2023034416A2 (en) * 2021-09-01 2023-03-09 Virtuoso Binco, Inc. Anti-icam1 antibodies and uses thereof
WO2023055376A1 (en) * 2021-09-30 2023-04-06 Virtuoso Binco, Inc. Multispecific antibodies for targeting cd47 and icam1 and methods of use thereof
KR102711074B1 (ko) * 2021-10-26 2024-10-04 재단법인 아산사회복지재단 암 생존자 유래 항체 및 이의 용도
WO2024207177A1 (en) * 2023-04-04 2024-10-10 Genequantum Healthcare (Suzhou) Co., Ltd. Antibody, linkers, payload, conjugates and applications thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250288611A1 (en) * 2024-03-04 2025-09-18 AffyImmune Therapeutics Inc. Icam-1 targeted car constructs and methods of treatment
CN118440185B (zh) * 2024-05-22 2024-11-19 宁夏大学 抗bhv-1的重组兔单克隆抗体及双抗体夹心elisa试剂和应用
WO2026038869A1 (ko) * 2024-08-12 2026-02-19 재단법인 아산사회복지재단 암 생존자 유래의 당쇄 특이적 항암 항체
CN119529093B (zh) * 2024-11-29 2026-03-06 武汉爱博泰克生物科技有限公司 一种抗人cd68单克隆抗体及其制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5892644A (ja) 1981-11-26 1983-06-02 Taiho Yakuhin Kogyo Kk 新規なニトロ安息香酸アミド誘導体およびそれを含有する放射線増感剤
US4694778A (en) 1984-05-04 1987-09-22 Anicon, Inc. Chemical vapor deposition wafer boat
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US5624925A (en) 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
US4921963A (en) 1987-04-13 1990-05-01 British Columbia Cancer Foundation Platinum complexes with one radiosensitizing ligand
JPH0819111B2 (ja) 1987-10-22 1996-02-28 ポーラ化成工業株式会社 2―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
FI950730A7 (fi) 1992-08-17 1995-04-10 Quadra Logic Tech Inc Menetelmä ei-toivottujen solujen tai kudosten kasvun tuhoamiseksi tai ehkäisemiseksi
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
US5599796A (en) 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
AU4188196A (en) 1994-12-22 1996-07-10 Nissan Chemical Industries Ltd. Organobismuth derivatives and process for producing the same
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5700825A (en) 1995-03-31 1997-12-23 Florida State University Radiosensitizing diamines and their pharmaceutical preparations
GB9816575D0 (en) 1998-07-31 1998-09-30 Zeneca Ltd Novel compounds
GB9818730D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
DE69930328T2 (de) 1998-08-27 2006-12-14 Spirogen Ltd., Ryde Dimere Pyrrolobenzodiazepine
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
GB0416511D0 (en) 2003-10-22 2004-08-25 Spirogen Ltd Pyrrolobenzodiazepines
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
US7335744B2 (en) * 2003-12-23 2008-02-26 The Regents Of The California University Prostate cancer specific internalizing human antibodies
JP5166861B2 (ja) 2004-03-09 2013-03-21 スピロゲン リミティッド ピロロベンゾジアゼピン
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
PL1879901T3 (pl) 2005-04-21 2010-06-30 Medimmune Ltd Pirolobenzodiazepiny
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
US8980833B2 (en) 2007-05-10 2015-03-17 R&D-Biopharmaceuticals Gmbh Tubulysine derivatives
PL2019104T3 (pl) 2007-07-19 2014-03-31 Sanofi Sa Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
GB0813432D0 (en) 2008-07-22 2008-08-27 Spirogen Ltd Pyrrolobenzodiazepines
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US8697688B2 (en) 2010-04-15 2014-04-15 Seattle Genetics Inc. Pyrrolobenzodiazepines used to treat proliferative diseases
MX391454B (es) 2010-04-15 2025-03-05 Seagen Inc Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
EP2580326A1 (en) 2010-06-11 2013-04-17 Antisense Pharma GmbH Method for selective oligonucleotide modification
EP2409983A1 (en) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Tubulysin analogues
CN102372778B (zh) * 2010-08-19 2015-06-17 上海抗体药物国家工程研究中心有限公司 抗人vegf和opn双特异性抗体、其制备方法及用途
CN103269712B (zh) 2010-11-03 2016-09-21 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
CN103648532A (zh) 2011-06-21 2014-03-19 伊缪诺金公司 具有肽连接子的新型美登木素生物碱衍生物及其偶联物
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
CN104244718A (zh) 2011-12-05 2014-12-24 伊格尼卡生物治疗公司 抗体-药物缀合物以及相关化合物、组合物和方法
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
RU2014153674A (ru) * 2012-06-05 2016-07-27 Регенерон Фармасьютикалз, Инк. Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
RU2015129800A (ru) 2012-12-21 2017-01-30 Биоэллаенс К. В. Гидрофильные саморазрушающиеся линкеры и их конъюгаты
US9701759B2 (en) * 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
SG11201507214SA (en) 2013-03-13 2015-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
WO2014197871A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-drug conjugates, compositions and methods of use
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
EP3126384B1 (en) 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
KR102095096B1 (ko) * 2015-08-26 2020-03-30 바이슨 테라퓨틱스 인크. 다중특이적 항체 플랫폼 및 관련 방법
EA201891732A1 (ru) 2016-02-02 2019-02-28 Кадмон Корпорейшн, Ллк Биспецифичные связывающие белки для pd-l1 и kdr
US12583932B2 (en) 2018-11-16 2026-03-24 Virtuoso Binco, Inc. CD38 and ICAM1 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
BR112021017339A2 (https=)
BR112021017637A2 (https=)
JP2022507485A5 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021017728A2 (https=)
BR112021013944A2 (https=)
BR112021017703A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021017173A2 (https=)
BR112021017083A2 (https=)
BR112021015080A2 (https=)
BR112021017310A2 (https=)
BR112021018484A2 (https=)
BR112021017847A2 (https=)
BR112021018851A2 (https=)
BR112021016979A2 (https=)
BR112021016784A2 (https=)
BR112021016205A2 (https=)
BR112021017010A2 (https=)